Portfolio item number 1
Short description of portfolio item number 1
Posts by Collection
portfolio
Portfolio item number 2
Short description of portfolio item number 2
publications
Line-of-sight pursuit in monotone and scallop polygons
Published in International Journal of Computational Geometry & Applications, 2015
This paper was the result of a 2012 Math REU jointly run by Macalester College and the Institute for Mathematics and its Applications at the University of Minnesota.
Recommended citation: Berry, L., Beveridge, A., Butterfield, J., Isler, I., Keller, Z., Shine, A., Wang, J. "Line-of-site pursuit in monotone and scallop polygons." 2019. International Journal of Computational Geometry & Applications. 29(4): 307-351. https://www.worldscientific.com/doi/abs/10.1142/S0218195919500122
Bayesian forecasting of many count-valued time series
Published in Journal of Business and Economic Statistics, 2019
This paper proposes the dynamic count mixture model (DCMM), a multi-scale extension, and discusses application to consumer sales forecasting.
Recommended citation: Berry, L.R., West, M. "Bayesian forecasting of many count-valued time series." 2019. Journal of Business and Economic Statistics. https://www.tandfonline.com/doi/abs/10.1080/07350015.2019.1604372
Probabilistic forecasting of heterogeneous consumer transaction-sales time series
Published in International Journal of Forecasting, 2020
This paper proposes the dynamic binary cascade model (DBCM) and an extension of the DCMM to forecast transaction-sales time series in consumer sales forecasting contexts.
Recommended citation: Berry, L.R., Helman, P., West, M. "Probabilistic forecasting of heterogeneous consumer transaction-sales time series." 2020. International Journal of Forecasting. https://www.sciencedirect.com/science/article/abs/pii/S0169207019302055
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
Published in JAMA, 2020
The first results of the REMAP-CAP study reported in JAMA on corticosteroid use for COVID-19.
Recommended citation: The Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324(13):1317–1329. doi:10.1001/jama.2020.17022 https://jamanetwork.com/journals/jama/fullarticle/2770278
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
Published in NEJM, 2021
Results from the REMAP-CAP trial: IL-6ra interventions are superior to control for patients with severe COVID-19. A fully Bayesian, adaptive platform trial.
Recommended citation: The REMAP-CAP Investigators. (2021) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med DOI: 10.1056/NEJMoa2100433 https://www.nejm.org/doi/full/10.1056/NEJMoa2100433
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization
Published in Trials, 2021
Summary of a study of comparative effectiveness of COVID-19 monoclonal antibodies with FDA EUA in the UPMC Health System.
Recommended citation: Huang, D.T., McCreary, E.K., Bariola, J.R. et al. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization. Trials 22, 363 (2021). https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05316-3
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis
Published in Journal of the American Medical Association, 2021
Meta-analysis estimating the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.
Recommended citation: The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. Published online July 06, 2021. doi:10.1001/jama.2021.11330 https://jamanetwork.com/journals/jama/fullarticle/2781880
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Published in Intensive Care Medicine, 2021
Results from the REMAP-CAP trial: Among critically ill patients with COVID-19, lopinavir-ritonavir, hydroxychloroquine, or combination therapy worsened outcomes compared to no antiviral therapy.
Recommended citation: Arabi, Y.M., Gordon, A.C., Derde, L.P.G. et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med 47, 867–886 (2021). https://link.springer.com/article/10.1007/s00134-021-06448-5
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Published in New England Journal of Medicine, 2021
In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis..
Recommended citation: The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. NEJM. Published online August 04, 2021. doi:10.1056/NEJMoa2105911 https://www.nejm.org/doi/full/10.1056/NEJMoa2105911
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Published in New England Journal of Medicine, 2021
In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis.
Recommended citation: The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. NEJM. Published online August 04, 2021. doi:10.1056/NEJMoa2103417 https://www.nejm.org/doi/full/10.1056/NEJMoa2103417
talks
Line-of-sight pursuit in monotone polygons
Published:
Line-of-sight pursuit in monotone polygons
Published:
Bayesian Dynamic Modeling and Forecasting of Count Time Series
Published:
Virtual seminar for the finalists of the Savage award to present their dissertation research.
Savage Award Session
Published:
Invited session for the finalists of the Savage award. I presented an overview of my doctoral research on Bayesian modeling and forecasting of time series of counts.
The statistical analysis of REMAP-CAP: A platform trial for COVID-19
Published:
Invited session for the session “Light methods for hard problems.”
Statistical Framework for the mpRCT of Therapeutic Anticoagulation in Covid-19
Published:
Livestream of the results of the mpRCT trial of therapeutic anticoagulation in Covid-19 hosted by Critical Care Reviews corresponding with publications released in NEJM.
teaching
Teaching experience 1
Undergraduate course, University 1, Department, 2014
This is a description of a teaching experience. You can use markdown like any other post.
Teaching experience 2
Workshop, University 1, Department, 2015
This is a description of a teaching experience. You can use markdown like any other post.